<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03124134</url>
  </required_header>
  <id_info>
    <org_study_id>GS-200-005</org_study_id>
    <secondary_id>160159</secondary_id>
    <nct_id>NCT03124134</nct_id>
  </id_info>
  <brief_title>Gelesis Glycemic Index Study</brief_title>
  <acronym>GLIDE</acronym>
  <official_title>A Randomized, Open-label, Crossover Study Assessing the Effects of Gelesis200 on Glucose and Insulin Following a Single Administration of Gelesis200 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gelesis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>inVentiv Health Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gelesis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to determine glucose and insulin responses to 50g and 100 g of carbohydrate with and&#xD;
      without Gelesis200.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single centre, open-label, randomized, single-administration, 4-period, 4-way,&#xD;
      crossover, pilot study with glycemic and insulin assessments. There is also an option for 2&#xD;
      additional single-administration periods based on the results of an interim analysis.&#xD;
&#xD;
      The study includes 2 treatments arms with Gelesis200 (4.20 g 10 minutes before a 50 g&#xD;
      carbohydrate breakfast and 4.20 g 10 minutes before a 100 g carbohydrate breakfast) plus 2&#xD;
      control arms consisting of consumption of the breakfasts with water only.&#xD;
&#xD;
      The optional periods consist of 1 treatment arm with Gelesis200 and 1 control arm with&#xD;
      breakfast and water only. Either only one or both the optional periods may be conducted. The&#xD;
      number of additional period(s) to conduct, the amount of Gelesis200 in the treatment arm, as&#xD;
      well as the meal composition will be based on interim analysis results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 18, 2017</start_date>
  <completion_date type="Actual">May 18, 2017</completion_date>
  <primary_completion_date type="Actual">May 18, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>4-way crossover with the option for 2 more crossover arms after interim analysis</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>single administration on each of up to 6 days over 6 weeks</time_frame>
    <description>AEs, lab abnormalities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post prandial glucose</measure>
    <time_frame>single administration on each of up to 6 days over 6 weeks</time_frame>
    <description>iAUC of glucose after a carbohydrate containing meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post prandial insulin</measure>
    <time_frame>single administration on each of up to 6 days over 6 weeks</time_frame>
    <description>iAUC of insulin after a carbohydrate containing meal</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Obesity</condition>
  <condition>Diabetes</condition>
  <condition>PreDiabetes</condition>
  <arm_group>
    <arm_group_label>A) Gelesis200, 50 g carbs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4.20 g of Gelesis200 before a 50 g carbohydrate breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B) Gelesis200, 100 g carbs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4.20 g of Gelesis200 before a 100 g carbohydrate breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C) Water, 50 g carbs</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>300 mL water before a 50 g carbohydrate breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D) Water, 100 g carbs</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>300 mL water before a 100 g carbohydrate breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E) Gelesis200, TBD carbs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>up to 4.20 g Gelesis200 before a meal of either 50 g or 100 g carbohydrate breakfast (to be determined after interim analysis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F) Water, TBD carbs</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>300 mL of water before a meal of either 50 g or 100 g carbohydrate breakfast (to be determined after interim analysis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gelesis200</intervention_name>
    <description>Encapsulated hydrogel</description>
    <arm_group_label>A) Gelesis200, 50 g carbs</arm_group_label>
    <arm_group_label>B) Gelesis200, 100 g carbs</arm_group_label>
    <arm_group_label>E) Gelesis200, TBD carbs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Water, only (placebo)</intervention_name>
    <description>300 mL of water</description>
    <arm_group_label>C) Water, 50 g carbs</arm_group_label>
    <arm_group_label>D) Water, 100 g carbs</arm_group_label>
    <arm_group_label>F) Water, TBD carbs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male.&#xD;
&#xD;
          2. Non-smoker (no use of tobacco products within 6 months prior to screening), ≥ 22 and ≤&#xD;
             65 years of age, with body mass index (BMI) ≥ 18.5 and &lt; 30.0 kg/m2.&#xD;
&#xD;
          3. Healthy as defined by:&#xD;
&#xD;
               1. the absence of clinically significant illness and surgery within 12 weeks prior&#xD;
                  to administration. Subjects vomiting within 24 hours pre-administration will be&#xD;
                  carefully evaluated for upcoming illness/disease. Inclusion pre-administration is&#xD;
                  at the discretion of the Qualified Investigator.&#xD;
&#xD;
               2. the absence of clinically significant history of neurological, endocrine,&#xD;
                  cardiovascular, pulmonary, hematological, immunologic, psychiatric,&#xD;
                  gastrointestinal, renal, hepatic, and metabolic disease, including, but not&#xD;
                  limited to pancreatitis, hepatitis B or C, HIV, swallowing disorders, and&#xD;
                  gastroesophageal reflux disease (at least 1 episode per week).&#xD;
&#xD;
               3. the absence of clinically significant history of gastric or peptic ulcer, small&#xD;
                  bowel resection (except if related to appendectomy), intestinal stricture (e.g.,&#xD;
                  Crohn's disease), intestinal obstruction or high risk of intestinal obstruction&#xD;
                  including suspected small bowel adhesions.&#xD;
&#xD;
               4. the absence of clinically significant history or known presence of esophageal&#xD;
                  anatomic abnormalities (e.g., webs, diverticuli, rings), gastroparesis, and&#xD;
                  malabsorption.&#xD;
&#xD;
               5. the absence of history of gastric bypass, any other gastric surgery and&#xD;
                  intragastric balloon.&#xD;
&#xD;
               6. the absence of history of angina, coronary bypass, and myocardial infarction&#xD;
                  within 6 months prior to administration.&#xD;
&#xD;
               7. the absence of history of abdominal radiation treatment.&#xD;
&#xD;
               8. the absence of history of cancer within the past 5 years, except&#xD;
                  adequately-treated localized basal cell skin cancer.&#xD;
&#xD;
          4. Capable of consent.&#xD;
&#xD;
          5. Fasting plasma glucose &lt; 100 mg/dL (&lt; 5.6 mmol/L) and fasting insulin &lt; 10 μIU/mL (&lt;&#xD;
             69.5 pmol/L) at screening.&#xD;
&#xD;
          6. Ability and willingness to consume 3 slices of white bread within 10 minutes and 6&#xD;
             slices of white bread within 15 minutes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any clinically significant abnormality or abnormal laboratory test results found&#xD;
             during medical screening or positive test for hepatitis B, hepatitis C, or HIV found&#xD;
             during medical screening.&#xD;
&#xD;
          2. Positive urine drug screen at screening.&#xD;
&#xD;
          3. History of allergic reactions to carboxymethylcellulose, citric acid, gelatin,&#xD;
             titanium dioxide, or other related substances.&#xD;
&#xD;
          4. Any reason which, in the opinion of the Qualified Investigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
&#xD;
          5. Clinically significant ECG abnormalities or vital sign abnormalities (systolic blood&#xD;
             pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or&#xD;
             over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.&#xD;
&#xD;
          6. History of significant alcohol abuse within one year prior to screening or regular use&#xD;
             of alcohol within six months prior to the screening visit (more than fourteen units of&#xD;
             alcohol per week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).&#xD;
&#xD;
          7. History of significant drug abuse within one year prior to screening or use of soft&#xD;
             drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs&#xD;
             (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and&#xD;
             amphetamine derivatives) within 1 year prior to screening.&#xD;
&#xD;
          8. Participation in a clinical research study involving the administration of an&#xD;
             investigational or marketed drug or device within 30 days prior to the first IP&#xD;
             administration, administration of a biological product in the context of a clinical&#xD;
             research study within 90 days prior to the first IP administration, or concomitant&#xD;
             participation in an investigational study involving no drug or device administration.&#xD;
&#xD;
          9. Use of medication other than topical products without significant systemic absorption:&#xD;
&#xD;
               1. prescription medication within 30 days prior to the first administration;&#xD;
&#xD;
               2. over-the-counter products and natural health products (including herbal remedies,&#xD;
                  homeopathic and traditional medicines, probiotics, food supplements such as&#xD;
                  vitamins, minerals, amino acids, essential fatty acids, and protein supplements&#xD;
                  used in sports) within 7 days prior to the first administration, with the&#xD;
                  exception of the occasional use of acetaminophen (up to 2 g daily);&#xD;
&#xD;
               3. a depot injection or an implant of any drug within 3 months prior to the first&#xD;
                  administration.&#xD;
&#xD;
         10. Donation of plasma within 7 days prior to administration. Donation or loss of blood&#xD;
             (excluding volume drawn at screening) of 50 mL to 499 mL within 30 days, or more than&#xD;
             499 mL within 56 days prior to the first administration.&#xD;
&#xD;
         11. Hemoglobin &lt; 128 g/L and hematocrit &lt; 0.37 L/L at screening.&#xD;
&#xD;
         12. Glycosylated hemoglobin (HbA1c) ≥ 6.5% (≥ 48 mmol/mol) at screening.&#xD;
&#xD;
         13. Serum low-density lipoprotein cholesterol ≥ 190 mg/dL (≥ 4.93 mmol/L) at screening.&#xD;
&#xD;
         14. Serum triglycerides ≥ 500 mg/dL (≥ 5.65 mmol/L) at screening.&#xD;
&#xD;
         15. Abnormal TSH at screening, or abnormal free T4 if TSH is slightly out of range.&#xD;
&#xD;
         16. Anticipating surgical intervention during the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Audet</last_name>
    <role>Principal Investigator</role>
    <affiliation>inVentiv Health Clinique</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>inVentiv Health Clinique</name>
      <address>
        <city>Quebec City</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The individual data will not be available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

